Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F-18]-T807

Journal of Alzheimer's Disease

Volumn 34, Issue 2, 2013, Pages 457-468

  Chien, David T ^a   Bahri, Shadfar ^b   Szardenings, A Katrin ^a   Walsh, Joseph C ^a   Mu, Fanrong ^a   Su, Min Ying ^b   Shankle, William R ^c   Elizarov, Arkadij ^a   Kolb, Hartmuth C ^a  

^a SIEMENS CORPORATE RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Hoag Neurosciences Institute   (United States)

Author keywords

Alzheimer's disease; amyloid ; brain imaging; mild cognitive impairment; molecular imaging; neurofibrillary tangles; paired helical filaments; tau; tau aggregates; tauopathy

Indexed keywords

AMYLOID BETA PROTEIN; RADIOPHARMACEUTICAL AGENT; T807 F 18; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE REPORT; CLINICAL TRIAL; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN TARGETING;

EID: 84874288678     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122059     Document Type: Article

References (19)

1. Alzheimer's Association (2012) Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168
2. Iqbal K, Liu F, Gong CX, Alonso Adel C, Grundke-Iqbal I (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol 118, 53-69
3. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT (1992) Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42, 631-639
4. Buchhave P, Minthon L, Zetterberg H, Wallin K, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of 2277;-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106
5. Benson A (2005) Alzheimer's disease: A tangled issue. Drug Discov Today 10, 749-751 (Pubitemid 40744917)
6. Chidambaram A, Frost&Sullivan Market Insight, July 4, 2012
7. Sabbagh M (2009) Drug development for Alzheimer's disease: Where are we now and where are we headed? Am J Geriatr Pharmacother 7, 167-185
8. America's Biopharmaceutical Research Companies (2012) Medicines in Development: Alzheimer's Disease, http:// phrma.org/sites/default/files/422/ alzheimers2012.pdf
9. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2, 605-613 (Pubitemid 37162569)
10. Shao X, Carpenter GM, Desmond TJ, Sherman P, Quesada CA, Fawaz M, Brooks AF, Kilbourn MR, Albin RL, Frey KA, Scott PJH (2012) Evaluation of 11C N-methyl lansoprazole as a radiopharmaceutical for PET imaging of tau neurofibrillary tangles. ACS Med Chem Lett 3, 936-941
11. Villemagne V, Furumoto S, Fodero-Tavoletti M, Harada R, Mulligan RS, Kudo Y, Masters CL, Yanai K, Rowe CC, Okamura N (2012) The challenges of tau imaging. Future Neurol 7, 409-421
12. Watanabe H, Ono M, Kimura H, Matsumura K, Yoshimura M, Okamoto Y, Ihara M, Takahashi R, Saji H (2012) Synthesis and biological evaluation of novel oxindole derivatives for imaging neurofibrillary tangles in Alzheimer's disease. Bioorg Med Chem Lett 22, 5700-5703
13. Villemagne V, Furumoto S, Fodero-Tavoletti M, Mulligan R, Hodges J, Kudo Y, Masters C, Yanai K, Rowe C, Okamura N (2012) In vivo tau imaging in Alzheimer's disease. J Nucl Med 53 (Suppl 1), 36
14. Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC (2012) A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 31, 601-612
15. Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198
16. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82, 239-259
17. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404 (Pubitemid 44469160)
18. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, Dannals RF, Nandi A, Bracsic JR, Ye W, Hilton J, Lyketsos C, Kung HF, Joshi AD, Skovronsky DM, Pontecorvo MJ (2010) In vivo imaging of amyloid deposition in Alzheimer's disease using the novel radioligand 18FAV-45 (Florbetapir F 18). J Nucl Med 51, 913-920
19. McNamee RL, Yee SH, Price JC, Klunk WE, Rosario B, Weissfeld L, Ziolko S, Berginc M, Lopresti B, DeKosky S, Mathis CA (2009) Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 50, 348-355